IL‐21 collaborates with anti‐TIGIT to restore NK cell function in chronic HBV infection

Abstract Available therapies for chronic hepatitis B virus (HBV) infection are not satisfying, and interleukin‐21 (IL‐21) and checkpoint inhibitors are potential therapeutic options. However, the mechanism underlying IL‐21 and checkpoint inhibitors in treating chronic HBV infection is unclear. To explore whether IL‐21 and checkpoint inhibitors promote HBV clearance by modulating the function of natural killer (NK) cells, we measured the phenotypes and functions of NK cells in chronic HBV‐infected patients and healthy controls on mRNA and protein levels. We found that chronic HBV infection disturbed the transcriptome of NK cells, including decreased expression of KLRK1, TIGIT, GZMA, PRF1 , and increased expression of CD69 . We also observed altered phenotypes and functions of NK cells in chronic HBV‐infected patients, characterized by decreased NKG2D expression, increased TIGIT expression and impaired interferon‐gamma (IFN‐γ), tumor necrosis factor‐alpha (TNF‐α) production. Furthermore, these alterations cannot be restored by telbivudine treatment but can be partially restored by IL‐21 and anti‐TIGIT stimulation. IL‐21 upregulated the expression of activating receptor CD16, CD69, and NKG2D on NK cells, enhanced IFN‐γ production, cytolysis, and proliferation of NK cells, while anti‐TIGIT promoted IFN‐γ production in CD56 dim subset exclusively in chronic HBV infected patients. Additionally, IL‐21 was indispensable for anti‐TIGIT in HBsAg clearance in mice bearing HBV. It enhanced IFN‐γ production in splenic NK cells rather than intrahepatic NK cells, indicating a brand‐new mechanism of IL‐21 in HBV clearance when combined with anti‐TIGIT. Overall, our findings contribute to the design of immunotherapy through enhancing the antiviral efficacy of NK cells in chronic HBV infection.